Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), recently completed the manufacture of a human rhinovirus Type 16 challenge stock. MLS manufactured the rhinovirus challenge stock under contract and according to the appropriate current Good Manufacturing Procedures (cGMPs) for use in early-phase human clinical trials while simultaneously meeting the desired titer specifications under aggressive timelines.
Challenge stocks are wild type, native viruses that are fully capable of causing disease in the target population. These virus preparations are designed to be used in conjunction with clinical trials testing the efficacy of a given therapeutic. A challenge stock of infectious virus permits infection of a group of healthy volunteers where the precise viral dose, timing and progression of disease can be monitored. In turn, administration of the anti-viral therapeutic or vaccine may be tested at varying times and doses to better understand the efficacy of the drug in a controlled environment. Beyond the advantages of providing a carefully monitored test environment, the use of a challenge stock in designing an efficacy study is the increased efficiency in patient enrollment, and time to completion of the study. In clinical efficacy trials that depend on the identification of randomly infected individuals for inclusion in the study, it is common to encounter long delays and difficulties with identification of appropriate test subjects. Studies utilizing challenge stocks such as the human rhinovirus permit rapid enrollment and testing of the therapeutic resulting in significant cost savings along the road to commercialization.
Victor Van Cleave, Ph.D., Vice President of Research and Development (R&D) at Meridian Life Science, stated, “MLS is pleased to have been selected for the cGMP manufacture of a human rhinovirus Type 16 challenge stock. This project, similar to other challenge stocks and vaccines we’ve produced, was an excellent fit for MLS’ core virology and virus-based product manufacturing capabilities. The contract manufacturing process required successful technology transfer and development of a scalable production process to make this challenge stock. MLS and our scientists are proud to be a part of this drug development effort that could significantly reduce the incidence and/or severity of rhinovirus infections.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV